Scandion Oncology

    OverviewSuggest Edit

    Scandion Oncology is a company developing drugs that specifically target chemotherapy resistance mechanisms. It aims to provide treatments that will re-sensitize cancer cells to chemotherapy within the metastatic colon and breast cancer. In addition, the company uses a screening platform that screens for the ability to restore drug sensitivity.

    HQKøbenhavn, DK

    Latest Updates

    Employees (est.) (Sept 2021)19(+6%)
    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at Scandion Oncology

    Christian Vinding Thomsen

    Christian Vinding Thomsen

    Peter Høngaard Andersen

    Peter Høngaard Andersen

    Chairman of the Board
    Peter Michael Vestlev

    Peter Michael Vestlev

    Chief Medical Officer
    Nicklas Lindland Roest

    Nicklas Lindland Roest

    Chief Regulatory Officer
    Thomas Feldthus

    Thomas Feldthus

    Bo Rode Hansen

    Bo Rode Hansen

    President & CEO and Member of the Board of Directors
    Show more

    Scandion Oncology Office Locations

    Scandion Oncology has an office in København
    København, DK (HQ)
    Fruebjergvej 3
    København, DK
    Carl Jacobsens Vej 35
    København, DK
    Ole Maaløes Vej 3
    Show all (3)

    Scandion Oncology Financials and Metrics

    Summary Metrics

    Founding Date


    Scandion Oncology Cybersecurity Score

    Cybersecurity ratingPremium dataset



    SecurityScorecard logo

    Scandion Oncology Online and Social Media Presence

    Embed Graph

    Scandion Oncology News and Updates

    Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy

    STOCKHOLM, Sept. 2, 2021 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), today announced the conclusion of their collaboration with a very positive outcome. The purpose of the collaboration was to explore the anti-tumor...

    Scandion Oncology Blogs

    Scandion Oncology announces that its President & CEO has bought 10,800 shares in Scandion Oncology

    Scandion Oncology A/S (“Scandion Oncology”) announces that its President & CEO, Bo Rode Hansen, has bought additional 10,800 shares in Scandion Oncology resulting in a total holding on 35,900 shares in the Company. For further information, please contact: Bo Rode Hansen, President & CEO Phon…

    Invitation to Scandion Oncology A/S audiocast on May 20, 2021

    We will publish our Interim Report for Q1 2021 on Thursday, May 20 and will be hosting a live audiocast later the same day at 10:00 am CET. Scandion Oncology will be represented by: Bo Rode Hansen President & CEO Carit Jacques Andersen CFO Scandion Oncology’s management team will present the hig…

    Scandion Oncology welcomes Mads Aaboe Jensen as VP for Business Development and Innovation

    Scandion Oncology announces the appointment of Mads Aaboe Jensen, PhD as VP for Business Development and Innovation. Mads brings to Scandion Oncology over 20 years of cancer biology experience and about 8 years of experience from the life science industry. He has previously worked with various aspec…

    2021 – a transformative year for Scandion Oncology

    The newly released 2020 annual report for Scandion Oncology summarises what was a year of evolution for the company, but also foreshadows big things to come in 2021. BioStock spoke to Scandion Oncology’s CEO Bo Rode Hansen to get his thoughts on the changes happening at Scandion and on what to look …

    Interview with COO and Head of R&D Operations Maj Hedtjärn in BioStock

    Read the interview with COO and Head of R&D Operations Maj Hedtjärn featured in BioStock here: Swedish, English Indlægget Interview with COO and Head of R&D Operations Maj Hedtjärn in BioStock blev først udgivet på Scandion Oncology.

    Scandion Oncology is recruiting a Financial Controller

    Be our new Financial Controller in a biotech company focused on developing drugs that specifically target chemotherapy resistance mechanisms. Scandion Oncology is a young, fast developing Copenhagen-based biotechnology company with an attractive pipeline. Scandion Oncology has two programs in clinic…
    Show more

    Scandion Oncology Frequently Asked Questions

    • When was Scandion Oncology founded?

      Scandion Oncology was founded in 2017.

    • Who are Scandion Oncology key executives?

      Scandion Oncology's key executives are Christian Vinding Thomsen, Peter Høngaard Andersen and Peter Michael Vestlev.

    • How many employees does Scandion Oncology have?

      Scandion Oncology has 22 employees.

    • Who are Scandion Oncology competitors?

      Competitors of Scandion Oncology include Rain Therapeutics, Medigen and Cascade Prodrug.

    • Where is Scandion Oncology headquarters?

      Scandion Oncology headquarters is located at Fruebjergvej 3, København.

    • Where are Scandion Oncology offices?

      Scandion Oncology has an office in København.

    • How many offices does Scandion Oncology have?

      Scandion Oncology has 3 offices.